| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
22,250 |
20,531 |
$3.04M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,408 |
3,241 |
$455K |
| T1015 |
Clinic visit/encounter, all-inclusive |
3,273 |
2,497 |
$412K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,743 |
2,731 |
$383K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,431 |
2,425 |
$344K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,444 |
1,416 |
$200K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
1,066 |
1,015 |
$145K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
694 |
671 |
$104K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,649 |
2,605 |
$64K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
6,140 |
5,999 |
$57K |
| 87428 |
|
708 |
693 |
$44K |
| 99188 |
|
1,917 |
1,901 |
$21K |
| 96160 |
|
1,383 |
1,350 |
$11K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
119 |
117 |
$6K |
| 92551 |
|
6,614 |
6,532 |
$6K |
| 87430 |
|
2,849 |
2,700 |
$5K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,913 |
1,735 |
$3K |
| 90461 |
|
1,863 |
1,826 |
$2K |
| 96127 |
|
1,659 |
1,607 |
$2K |
| 97802 |
|
252 |
252 |
$1K |
| 90686 |
|
2,951 |
2,890 |
$1K |
| 99051 |
|
88 |
79 |
$949.50 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
36 |
36 |
$700.00 |
| 90677 |
|
12 |
12 |
$509.95 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,160 |
1,132 |
$414.79 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
312 |
303 |
$399.64 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
90 |
87 |
$187.31 |
| 90723 |
|
41 |
40 |
$180.00 |
| 90670 |
|
175 |
173 |
$166.28 |
| 85018 |
|
150 |
148 |
$54.71 |
| 90647 |
|
38 |
36 |
$49.44 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
29 |
28 |
$40.92 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
26 |
25 |
$37.20 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
79 |
78 |
$30.41 |
| 81003 |
|
29 |
26 |
$13.58 |
| 99173 |
|
3,326 |
3,257 |
$13.20 |
| 80061 |
Lipid panel |
61 |
57 |
$9.29 |
| 81005 |
|
100 |
100 |
$8.06 |
| 90715 |
|
55 |
55 |
$4.16 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
108 |
101 |
$0.00 |
| 90756 |
|
41 |
41 |
$0.00 |
| 83655 |
|
26 |
25 |
$0.00 |
| 90734 |
|
36 |
36 |
$0.00 |
| 90633 |
|
13 |
13 |
$0.00 |
| G9153 |
Mapcp demonstration - physician incentive pool |
965 |
952 |
$0.00 |
| 87449 |
|
150 |
134 |
$0.00 |
| 90651 |
|
83 |
82 |
$0.00 |
| 90716 |
|
13 |
12 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
41 |
41 |
$0.00 |
| 87807 |
|
28 |
27 |
$0.00 |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
53 |
53 |
$0.00 |
| 87081 |
|
12 |
12 |
$0.00 |